Presentation is loading. Please wait.

Presentation is loading. Please wait.

Limited access safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent or persistent.

Published byBenjamin Visser Modified over 5 years ago

Similar presentations

Presentation on theme: "Limited access safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent or persistent."— Presentation transcript:

1 Limited access safety lead-in of the MEK inhibitor trametinib in combination with GSK , an AKT inhibitor, in patients with recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study  S.N. Westin, M. Sill, R.L. Coleman, S.E. Waggoner, K.N. Moore, C.A. Mathews, A. Jain, S.C. Modesitt, R. Schilder, C. Aghajanian  Gynecologic Oncology  Volume 141, Pages 4-5 (June 2016) DOI: /j.ygyno Copyright © Terms and Conditions

2 Fig. 1 Progression-Free Survival by Treatment Levels.
Gynecologic Oncology  , 4-5DOI: ( /j.ygyno ) Copyright © Terms and Conditions

Download ppt "Limited access safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent or persistent."

Similar presentations

Nicoletta Colombo, Martin Gore 

Nicoletta Colombo, Martin Gore 
Volume 144, Issue 1, Pages (January 2017)

Volume 144, Issue 1, Pages (January 2017)
Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade.

Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade.
Volume 150, Issue 1, Pages (July 2018)

Volume 150, Issue 1, Pages (July 2018)
Volume 148, Issue 1, Pages (January 2018)

Volume 148, Issue 1, Pages (January 2018)
Are patients willing to travel for better ovarian cancer care?

Are patients willing to travel for better ovarian cancer care?
Volume 148, Issue 1, Pages (January 2018)

Volume 148, Issue 1, Pages (January 2018)
L. C. Parsons, S. A. Sullivan, C. Garcia, T. Castellano, V. L

L. C. Parsons, S. A. Sullivan, C. Garcia, T. Castellano, V. L
Volume 148, Issue 1, Pages (January 2018)

Volume 148, Issue 1, Pages (January 2018)
Volume 150, Issue 3, Pages (September 2018)

Volume 150, Issue 3, Pages (September 2018)
A. Melamed, E. J. Diver, A. A. Gockley, E. M. Hinchcliff, L

A. Melamed, E. J. Diver, A. A. Gockley, E. M. Hinchcliff, L
Pain in cancer survivors; filling in the gaps

Pain in cancer survivors; filling in the gaps
Volume 149, Issue 2, Pages (May 2018)

Volume 149, Issue 2, Pages (May 2018)
Volume 145, Issue 2, Pages (May 2017)

Volume 145, Issue 2, Pages (May 2017)
Volume 138, Issue 1, Pages (July 2015)

Volume 138, Issue 1, Pages (July 2015)
Vulvar intraepithelial neoplasia: Risk factors for recurrence

Vulvar intraepithelial neoplasia: Risk factors for recurrence
Joachim Pfannschmidt, MD, Hans Hoffmann, MD, Hendrick Dienemann, MD 

Joachim Pfannschmidt, MD, Hans Hoffmann, MD, Hendrick Dienemann, MD 
The efficacy of mTORC1/2 inhibition on ovarian cancer stem cells

The efficacy of mTORC1/2 inhibition on ovarian cancer stem cells
Volume 152, Issue 1, Pages (January 2019)

Volume 152, Issue 1, Pages (January 2019)
Volume 141, Issue 2, Pages (May 2016)

Volume 141, Issue 2, Pages (May 2016)

Similar presentations

Ads by Google